Novo Nordisk reports increased Q1 2021 profit
Novo Nordisk has reported a net profit of kr12.6bn ($2.03bn) for the first quarter (Q1) of 2021, which represents an increase of 6% compared to kr11.9bn ($1.92bn) in Q1 2020.
Drug Development
ViiV Healthcare starts rolling submission of cabotegravir for HIV prevention
ViiV Healthcare has begun a rolling submission of a new drug application (NDA) with the...
CytoReason Q&A: moving beyond animal testing in drug research
While animal testing is the first step in the clinical development of any drug, animals often prove to be unreliable...
FDA approves AstraZeneca’s Farxiga for chronic kidney disease treatment
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Farxiga (dapagliflozin) for treating chronic kidney disease (CKD) in patients who are...
Bristol Myers Squibb revenues increase in Q1 2021
Bristol Myers Squibb has reported revenues of $11.1bn for the first quarter of this year, which represents an increase of...
GSK reports decline in Q1 2021 revenue due to Covid-19 disruption
GlaxoSmithKline (GSK) has reported an 18% year-on-year (YOY) decline in revenue in the first quarter of this year to £7.41bn and down 15% at constant currency due to disruption caused…
Pfizer acquires Amplyx Pharmaceuticals to advance anti-infectives pipeline
Pfizer has acquired US-based Amplyx Pharmaceuticals to advance its expertise in infectious disease and expand its anti-infectives pipeline. Amplyx focuses on developing treatments for life-threatening diseases that affect individuals with…
Science park merger creates UK’s largest life sciences ecosystem
US real estate investment company Harrison Street and UK real estate group Trinity Investment Management this week announced their joint acquisition of Nottingham-based science business incubator BioCity. The £120m deal…
CHMP suggests AstraZeneca and Merck’s selumetinib for paediatric patients
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended AstraZeneca and Merck’s (MSD) selumetinib for conditional marketing authorisation in the EU for…
Antibiotic resistance: how Covid-19 could be accelerating the ‘silent pandemic’
Long before the outbreak of Covid-19, another health emergency has posed a threat to life as we know it. Antibiotic resistance, which occurs when bacterial infections cease to respond to…
Vertex and Obsidian enter agreement to develop gene-editing treatments
Vertex Pharmaceuticals (VRTX) and Obsidian Therapeutics have entered a strategic research partnership and licensing agreement to discover and develop novel therapies that regulate gene editing for treating serious diseases. In…
